Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

DISCOVERY DIAGNOSTIC LABORATORY INC

NPI: 1669733697 · MARLBOROUGH, MA 01752 · Clinical Medical Laboratory · NPI assigned 06/06/2012

OIG Excluded Provider · This provider appears on the HHS Office of Inspector General List of Excluded Individuals/Entities. Exclusion date: 08/20/2025.
$698K
Total Medicaid Paid
10,734
Total Claims
4,387
Beneficiaries
3
Codes Billed
2018-01
First Month
2019-06
Last Month

Provider Details

Authorized OfficialSTEINHARDT, ANGELA (LABORATORY DIRECTOR)
NPI Enumeration Date06/06/2012

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 9,920 $687K
2019 814 $11K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 4,805 2,076 $372K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 5,719 2,217 $318K
80307 210 94 $8K